Revenue from Contracts with Customers (Tables)

6 Months Ended

Jun. 30, 2020

Revenue from Contracts with Customers

Summary of product revenue provision and allowance

					Trade
	Rebates and		Product		Allowances and
Six months ended June 30, 2020	Incentives (1)		Returns (2)		Chargebacks (3)
Balance at December 31, 2019	$	129,901	$	27,648	$	14,020
Provision related to current period sales		162,637		6,703		37,230
Changes in estimate related to prior period sales		(171)		—		85
Credits/payments made		(154,145)		(1,520)		(36,482)
Balance at June 30, 2020	$	138,222	$	32,831	$	14,853

					Trade
	Rebates and		Product		Allowances and
Six months ended June 30, 2019	Incentives (1)		Returns (2)		Chargebacks (3)
Balance at December 31, 2018	$	129,318	$	15,465	$	14,841
Provision related to current period sales		128,509		9,150		31,988
Changes in estimate related to prior period sales		(3,017)		—		—
Credits/payments made		(119,659)		(1,502)		(32,673)
Balance at June 30, 2019	$	135,151	$	23,113	$	14,156

(1)	Provisions for rebates and incentives includes managed care rebates, government rebates and co-pay program incentives. Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Consolidated Condensed Balance Sheets.
(2)	Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Condensed Consolidated Balance Sheets.
(3)		Provisions for trade allowances and chargebacks include fees for distribution service fees, prompt pay discounts, and chargebacks. Trade allowances and chargebacks are deducted from gross revenue at the time revenues are recognized and are recorded as a reduction to accounts receivable in the Company’s Condensed Consolidated Balance Sheets.

Schedule of disaggregation of revenue

	Three months ended June 30,				Six months ended June 30,
	2020		2019		2020		2019
Xtampza ER	$	33,557	$	26,018	$	65,064	$	51,152
Nucynta Products(1)		44,501		49,022		89,505		98,404
Total product revenues, net	$	78,058	$	75,040	$	154,569	$	149,556

(1) For the three months ended June 30, 2020, the Company recognized Nucynta IR and Nucynta ER product revenues, net of $29,073 and $15,427, respectively. For the three months ended June 30, 2019, the Company recognized Nucynta IR and Nucynta ER product revenues, net of $29,461 and $19,561, respectively. For the six months ended June 30, 2020, the Company recognized Nucynta IR and Nucynta ER product revenues, net of $57,044 and $32,461, respectively. For the six months ended June 30, 2019, the Company recognized Nucynta IR and Nucynta ER product revenues, net of $59,322 and $39,082, respectively. ​